Experimental CAR-T therapy takes aim at Hard-to-Treat lupus kidney disease

NCT ID NCT07364396

Not yet recruiting Disease control Sponsor: Curocell Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the disease. About 39 adults who have not responded to standard treatments will receive a single infusion of CRC01 and be monitored for safety and kidney improvement over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CRC01 (a CAR-T cell therapy made from the patient's own immune cells, modified to target and destroy certain immune cells)
What this could lead to: If successful, this could point toward a new treatment option for people with severe lupus nephritis that hasn't responded to other therapies.
What could go wrong: This is an early-phase trial with only 39 participants, so results may not apply to everyone. There are known risks like cytokine release syndrome and neurotoxicity, and the therapy may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS LUPUS NEPHRITIS (LN) SLE SLE (SYSTEMIC LUPUS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.